Ongoing trials are evaluating whether adding a second checkpoint inhibitor (such as an anti-CTLA-4 antibody) to PD-1 blockade plus chemotherapy can deepen responses, or if novel checkpoints (LAG-3, TIGIT, etc.)might further augment anti-tumor immunity in BTC. This evidence concerns the gene PDCD1 and neoplasm.